Crossover Trial of Mazindol for Cocaine Dependence

Abstract
Mazindol, an indirect dopamine agonist, was given at 2 mg qd to 19 cocaine‐dependent, methadone‐maintained patients during a 2‐week, placebo‐controlled, crossover trial. Patients showed no significant reduction in cocaine use, but they had increased cocaine craving on mazindol compared with placebo.